

PA Criteria	Criteria Details						
Covered Uses (FDA approved indication)	Rebyota suspension is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI. Currently, there are no compendia supported uses for this therapy outside the FDA-indication(s).						
Exclusion Criteria	None.						
Required Medical Information	Medical records supporting the request, including documentation of prior therapies and responses to treatment must be provided.						
Age Restriction	Must be 18 years of age or older.						
Prescriber Restrictions	None.						
Coverage Duration	One treatment course per FDA label and/or accepted standards of medical practice.						
Other Criteria/Information	Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document. <table border="1" data-bbox="500 926 1511 1073"> <thead> <tr> <th>HCPCS</th> <th>Description</th> <th>Billing Units/How Supplied</th> </tr> </thead> <tbody> <tr> <td>J1440</td> <td>Rebyota (fecal microbiota live-jslm)</td> <td>Billing unit: 1 ml 150ml Rectal Suspension</td> </tr> </tbody> </table>	HCPCS	Description	Billing Units/How Supplied	J1440	Rebyota (fecal microbiota live-jslm)	Billing unit: 1 ml 150ml Rectal Suspension
HCPCS	Description	Billing Units/How Supplied					
J1440	Rebyota (fecal microbiota live-jslm)	Billing unit: 1 ml 150ml Rectal Suspension					

STATUS	DATE REVISED	REVIEW DATE	APPROVED/REVIEWED BY	EFFECTIVE DATE
Created	3/26/2025	3/26/2025	Dawn Shojai, PharmD, Senior Pharmacy Benefit Consultant (PSG)	N/A
Approved	N/A	8/21/2025	Pharmacy & Therapeutics (P&T) Committee	8/21/2025